Related references
Note: Only part of the references are listed.The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation
A. Y. Ali et al.
ONCOGENE (2012)
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
J. M. R. Lambert et al.
ONCOGENE (2010)
Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein
M. R. Abedini et al.
ONCOGENE (2010)
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
K. G. Wiman
ONCOGENE (2010)
Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
X. Yang et al.
BRITISH JOURNAL OF CANCER (2008)
Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells
Mohammad R. Abedini et al.
CANCER RESEARCH (2008)
PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells
R. Magrini et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2
J. Shen et al.
ONCOGENE (2008)
PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status
Stephane Supiot et al.
RADIOTHERAPY AND ONCOLOGY (2008)
Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function
Michael Fraser et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Coping with stress: multiple ways to activate p53
H. F. Horn et al.
ONCOGENE (2007)
PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax
Tao Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitocliondrial death pathway
XK Yang et al.
CANCER RESEARCH (2006)
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
H Nahi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
VJN Bykov et al.
ONCOGENE (2005)
PI3K/Akt signalling pathway and cancer
JAF Vara et al.
CANCER TREATMENT REVIEWS (2004)
Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro
MR Abedini et al.
ONCOGENE (2004)
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
H Nahi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
PI3K/Akt and apoptosis: size matters
TF Franke et al.
ONCOGENE (2003)
Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription
JE Chipuk et al.
CANCER CELL (2003)
AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1 - Implication of AKT2 in chemoresistance
ZQ Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors
LM Kmet et al.
CANCER (2003)
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
VJN Bykov et al.
CARCINOGENESIS (2002)
The IARC TP53 database: New Online mutation analysis and recommendations to users
M Olivier et al.
HUMAN MUTATION (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus
LD Mayo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells
M Sun et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
